Search
Close this search box.

Publications from Research Funded by Open Medicine Foundation

We are excited to share a comprehensive overview of the publications that have resulted from research funded by Open Medicine Foundation. Our dedicated team of researchers and collaborators has been at the forefront of uncovering the complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This eblast will guide you through the various categories of our publications, each shedding light on different aspects of these conditions.

 


  

Pathophysiological Implications 

Publications in this category include findings that provide insights into the underlying biological mechanisms, pathways, and processes driving disease. These findings may help explain symptoms and overall pathology to inform treatment approaches.

Metabolic Dysfunction

  • Metabolic Features of Chronic Fatigue Syndrome by Robert Naviaux, Stanford Collaboration
 

Blood Flow Dysfunction

  • Insights from Invasive Cardiopulmonary Exercise Testing by David Systrom, Harvard Collaboration
 

Cellular Abnormalities (RBCs) & Blood Flow Dysfunction

  • Red Blood Cell Deformability is Diminished in Patients with Chronic Fatigue Syndrome by Anand Ramasubramanian and Ronald Davis, Stanford Collaboration
  • Phenotypic Characteristics of Peripheral Immune Cells of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome via Transmission Electron Microscopy: A Pilot Study by Fereshteh JahanbaniI, Rajan D. Maynard, Justin Cyril Sing, Shaghayegh Jahanbani, John J. Perrino, Damek V. Spacek, Ronald W. Davis, Michael P. Snyder, Stanford Collaboration
 

Autoantibody Immunological Findings

  • Autoantibodies to Beta Adrenergic and Muscarinic Cholinergic Receptors in Myalgic Encephalomyelitis (ME) patients by Jonas Bergquist, Uppsala Collaboration
 

Metabolic Trap

  • The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS by Robert D. Phair, and Ron Davis, Stanford Collaboration
 

Sex Hormones

  • The Underlying Sex Differences in Neuroendocrine Adaptations Relevant to Myalgic Encephalomyelitis / Chronic Fatigue Syndrome by Natalie Thomas, Caroline Gurvich, Katherine Huang, Paul R Gooley, Christopher W Armstrong, Melbourne Collaboration
 

Cardiopulmonary Abnormalities

  • Exercise Pathophysiology in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome and Post- Acute Sequelae of SARS- CoV-2: More in Common Than Not? by David Systrom, Harvard Collaboration
 
 

 

Comparative Pathophysiology

Publications in this category include findings that compare the molecular, cellular, and physiological disruptions in ME/CFS to analogous mechanisms in related diseases. By identifying convergent pathological processes and therapeutic targets across conditions, this approach can expedite understanding of ME/CFS pathogenesis and translation of insights into clinical diagnoses and treatments 

Post Viral Inflammatory Response

  • Temporal pathway analysis of cerebrospinal fluid proteome in herpes simplex encephalitis by Anja Nääs, Peng Li, Clas Ahlm, Elisabeth Aurelius, Josef D. Järhult, Silvia Schliamser, Marie Studahl, Wenzhong Xiao, Jonas Bergquist & Gabriel Westman
  • Acute Necrotizing Encephalopathy with SARS-CoV-2-RNA Confirmed in Cerebrospinal Fluid by Jonas Bergquist, Uppsala Collaboration
  • Predictors of post-COVID-19 and the impact of persistent symptoms in non-hospitalized patients 12 months after COVID-19, with a focus on work ability by Marta A Kisiel, Helena Janols, Tobias Nordqvist, Jonas Bergquist, Simone Hagfeld, Andrew Malinovschi, and Mangus Svartengren, Uppsala Collaboration
 

Injury and Inflammatory

  • Lessons from Heat Stroke for Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by Dominic Stanculescu, Nuno Sapúlveda, Chin Leong Lim, and Jonas Bergquist, Uppsala Collaboration
  • Drawing on Findings from Critical Illness to Explain Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome by Jonas Bergquist and Dominic Stanculescu, Uppsala Collaboration
 

Metabolic and Inflammatory Dysregulation

  • Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) by Jonas Bergquist, Uppsala Collaboration
  • Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) by Dominic Stanculescu, Lars Larsson, and Jonas Bergquist, Uppsala Collaboration
 
 

 

Diagnostic Implications

Publications in this category include findings that could contribute to developing or validating objective measures that accurately identify a disease. These findings include studies evaluating the accuracy of biomarker panels, novel imaging modalities, or microfluidic technologies to diagnose ME/CFS.

Molecular Signatures

  • Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology by Alain Moreau, Montreal Collaboration
  • Systematic Review of NMR-Based Metabolomics Practices in Human Disease Research by Katherine Huang, Natalie Thomas, Paul R. Gooley, Christopher W. Armstrong, Melbourne Collaboration
 

Microfluidic Chip Assay

  • A Nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) by Rahim Esfandyarpour, and Ronald W. Davis, Stanford Collaboration
  • Microfluidic Point-of-Care Testing: Commercial Landscape and Future Directions by Ronald Davis, and Amit K Saha, Stanford Collaboration
 
 

 

Prognostic Implication

The publications in this category includes findings that aim to identify indicators such as biomarkers that correlate with disease progression, severity subgroups, or likely recovery trajectories in ME/CFS patients. This category includes findings that may help predict outcomes and inform clinical decision-making.

  • A Comprehensive Examination of Severely Ill ME/CFS Patients by Ronald Davis and Wenzhong Xiao, Stanford Collaboration
 
 

 

Therapeutic Implication 

Publications in this category include findings that identify potential therapeutic targets or enable developing treatments. This includes research that directly test and evaluate specific treatments, interventions, or management approaches in ME/CFS patients. These studies assess potential solutions to manageME/CFS.

  • Neurovascular Dysregulation and Acute Exercise Intolerance in ME/CFS: A Randomized, Placebo-Controlled Trial of Pyridostigmine by Phillip Joseph, Rosa Pari, Sarah Miller, Arabella Warren, Mary Catherine Stovall, Johanna Squires, Chia-Jung Chang, Wenzhong Xiao, Aaron,B. Waxman, David M. Systrom, Harvard Collaboration
  • Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers by Jonas Bergquist, Uppsala Collaboration
 
 

 

Patient Care Case Study

  • When a 17-Year-Old Girl Is Diagnosed with Myalgic Encephalomyelitis: A Case Study from the Swedish Health Care System—A Parent Perspective by Eva Bojner Horwitz, Jonas Axelsson, Olli Polo, Leif Widebert, Töres Theorell, Anabelle Paulino, David Ullman, and Jonas Bergquist.
 
 

 

Please click here for the publication links. 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669